Akebia Therapeutics, Inc.

NasdaqCM:AKBA 주식 보고서

시가총액: US$390.5m

Akebia Therapeutics 관리

관리 기준 확인 3/4

Akebia Therapeutics CEO는 John Butler, Sep2013 에 임명되었습니다 의 임기는 11.17 년입니다. 총 연간 보상은 $ 2.78M, 28.7% 로 구성됩니다. 28.7% 급여 및 71.3% 보너스(회사 주식 및 옵션 포함). 는 $ 2.63M 가치에 해당하는 회사 주식의 0.67% 직접 소유합니다. 2.63M. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 5.9 년입니다.

주요 정보

John Butler

최고 경영자

US$2.8m

총 보상

CEO 급여 비율28.7%
CEO 임기11.2yrs
CEO 소유권0.7%
경영진 평균 재임 기간1.8yrs
이사회 평균 재임 기간5.9yrs

최근 관리 업데이트

Recent updates

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41%

Nov 08
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41%

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Aug 02
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)

Apr 02

There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise

Mar 19
There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

Jan 05
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump

Jun 23
Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump

Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?

Mar 02
Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?

Akebia Therapeutics: FDA Approval Failure, Terminated Partnerships, And Looming LOE - Too Risky

Oct 07

Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging Higher

Aug 10
Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging Higher

Akebia regains rights to kidney disease therapy after termination of deals with Otsuka

Jun 30

CEO 보상 분석

John Butler 의 보수는 Akebia Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$46m

Jun 30 2024n/an/a

-US$40m

Mar 31 2024n/an/a

-US$43m

Dec 31 2023US$3mUS$796k

-US$52m

Sep 30 2023n/an/a

-US$59m

Jun 30 2023n/an/a

-US$98m

Mar 31 2023n/an/a

-US$58m

Dec 31 2022US$3mUS$765k

-US$94m

Sep 30 2022n/an/a

-US$158m

Jun 30 2022n/an/a

-US$163m

Mar 31 2022n/an/a

-US$276m

Dec 31 2021US$3mUS$718k

-US$282m

Sep 30 2021n/an/a

-US$299m

Jun 30 2021n/an/a

-US$300m

Mar 31 2021n/an/a

-US$392m

Dec 31 2020US$6mUS$696k

-US$385m

Sep 30 2020n/an/a

-US$391m

Jun 30 2020n/an/a

-US$386m

Mar 31 2020n/an/a

-US$268m

Dec 31 2019US$4mUS$648k

-US$280m

Sep 30 2019n/an/a

-US$245m

Jun 30 2019n/an/a

-US$217m

Mar 31 2019n/an/a

-US$193m

Dec 31 2018US$3mUS$595k

-US$144m

Sep 30 2018n/an/a

-US$68m

Jun 30 2018n/an/a

-US$65m

Mar 31 2018n/an/a

-US$53m

Dec 31 2017US$3mUS$543k

-US$74m

보상 대 시장: John 의 총 보상 ($USD 2.78M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 2.24M ).

보상과 수익: John 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

John Butler (60 yo)

11.2yrs

테뉴어

US$2,775,123

보상

Mr. John P. Butler, MBA, serves as Non-Executive Director at Wren Therapeutics Limited since 2023. He has been the Chief Executive Officer and President of Akebia Therapeutics, Inc. since September 2013 an...

리더십 팀

이름위치테뉴어보상소유권
John Butler
CEO, President & Director11.2yrsUS$2.78m0.67%
$ 2.6m
Steven Burke
Senior VP of Research & Development and Chief Medical Officer5.3yrsUS$1.21m0.16%
$ 613.7k
Erik Ostrowski
Senior VPless than a year데이터 없음데이터 없음
Richard Malabre
Chief Accounting Officerless than a year데이터 없음데이터 없음
Kimberly Garko
Senior VP & Chief Technical Officerless than a year데이터 없음데이터 없음
Tracey Vetterick
Vice President of Portfolio Strategy & Corporate Administration1.8yrs데이터 없음데이터 없음
Mercedes Carrasco
Senior Director of Investor & Corporate Communicationsno data데이터 없음데이터 없음
Carolyn Rucci
Senior VP of Legal2.8yrs데이터 없음데이터 없음
Meredith Bowman
Senior VP & Chief People Officer2.8yrs데이터 없음데이터 없음
Nicholas Grund
Senior VP & Chief Commercial Officerless than a year데이터 없음데이터 없음

1.8yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: AKBA 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름위치테뉴어보상소유권
John Butler
CEO, President & Director11.3yrsUS$2.78m0.67%
$ 2.6m
Michael Rogers
Independent Director5.9yrsUS$145.79k0.044%
$ 171.9k
Adrian Adams
Independent Chairperson5.9yrsUS$171.63k0.062%
$ 241.3k
LeAnne Zumwalt
Independent Director3.8yrsUS$143.31k0.020%
$ 78.2k
Ronald Frieson
Independent Director3yrsUS$147.97k0.020%
$ 78.2k
Steven Gilman
Independent Director5.9yrsUS$139.87k0.040%
$ 155.9k
Cynthia Smith
Independent Director6.3yrsUS$151.50k0.044%
$ 170.5k
Myles Wolf
Independent Director4.6yrsUS$144.43k0.031%
$ 121.1k

5.9yrs

평균 재임 기간

64.5yo

평균 연령

경험이 풍부한 이사회: AKBA 의 이사회는 경험(평균 재직 기간 5.9 년)으로 간주됩니다.